Clive G. Ballard, MB ChB, MRCPsych, MD
Affiliations: | Age-Related Diseases | King's College London, London, UK |
Area:
http://www.researchprofiles.collexis.com/jad/expert.asp?u_id=109Google:
"Clive Ballard"Bio:
http://alzheimers.org.uk/site/scripts/documents_info.php?documentID=1137&pageNumber=2
http://www.biomedexperts.com/Profile.bme/74848/Clive_G_Ballard
http://uk.linkedin.com/pub/clive-ballard/a/b19/285
Mean distance: 106866
Cross-listing: Alzheimer's Tree
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Canal-Garcia A, Branca RM, Francis PT, et al. (2024) Proteomic signatures of Alzheimer's disease and Lewy body dementias: A comparative analysis. Alzheimer's & Dementia : the Journal of the Alzheimer's Association |
| Ismail Z, Leon R, Creese B, et al. (2023) Optimizing detection of Alzheimer's disease in mild cognitive impairment: a 4-year biomarker study of mild behavioral impairment in ADNI and MEMENTO. Molecular Neurodegeneration. 18: 50 |
| Chai YL, Lee JH, Chong JR, et al. (2023) Inflammatory panel cytokines are elevated in the neocortex of late-stage Alzheimer's disease but not Lewy body dementias. Journal of Neuroinflammation. 20: 111 |
| Creese B, Arathimos R, Aarsland D, et al. (2023) Late-life onset psychotic symptoms and incident cognitive impairment in people without dementia: Modification by genetic risk for Alzheimer's disease. Alzheimer's & Dementia (New York, N. Y.). 9: e12386 |
| Garcia MJ, Leadley R, Lang S, et al. (2022) Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease. Journal of Alzheimer's Disease : Jad |
| Sabatini S, Martyr A, Ukoumunne OC, et al. (2022) Attitudes toward own aging and cognition among individuals living with and without dementia: findings from the IDEAL programme and the PROTECT study. Bmc Geriatrics. 22: 641 |
| Tariot PN, Ballard C, Devanand DP, et al. (2022) Pimavanserin and dementia-related psychosis. The Lancet. Neurology. 21: 114-115 |
| Ismail Z, Creese B, Aarsland D, et al. (2022) Psychosis in Alzheimer disease - mechanisms, genetics and therapeutic opportunities. Nature Reviews. Neurology |
| Banerjee S, High J, Stirling S, et al. (2021) Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 398: 1487-1497 |
| Tariot PN, Cummings JL, Soto-Martin ME, et al. (2021) Trial of Pimavanserin in Dementia-Related Psychosis. The New England Journal of Medicine. 385: 309-319 |